What is she best known for?
The fields of study she is best known for:
- Internal medicine
- Cancer
- Chemotherapy
Gillian M. Keating focuses on Internal medicine, Surgery, Tolerability, Anesthesia and Pharmacology.
Her research integrates issues of Gastroenterology, Type 2 diabetes and Oncology in her study of Internal medicine.
Her Surgery research incorporates themes from Prostatectomy, Arthritis, Plerixafor, Rheumatology and Management of Parkinson's disease.
Her Tolerability research is multidisciplinary, incorporating elements of Extrapyramidal symptoms, Antipsychotic, Atypical antipsychotic, Sorafenib and Psychiatry.
Her work on Sedative, Diclofenac and Acetaminophen as part of general Anesthesia research is frequently linked to Sodium salt, thereby connecting diverse disciplines of science.
Her Pharmacology study combines topics in areas such as Narcotic antagonist, Buprenorphine, Clonidine and Opioid antagonist.
Her most cited work include:
- Sorafenib: a review of its use in advanced hepatocellular carcinoma. (337 citations)
- Zolpidem: a review of its use in the management of insomnia. (250 citations)
- Recombinant hepatitis B vaccine (Engerix-B): a review of its immunogenicity and protective efficacy against hepatitis B. (184 citations)
What are the main themes of her work throughout her whole career to date?
The scientist’s investigation covers issues in Internal medicine, Adverse effect, Tolerability, Anesthesia and Pharmacotherapy.
Her Internal medicine research is multidisciplinary, relying on both Gastroenterology, Endocrinology, Surgery and Oncology.
Her research in Oncology intersects with topics in Cancer, Metastatic breast cancer and Chemotherapy.
Adverse effect is closely attributed to Clinical endpoint in her research.
Her research on Tolerability concerns the broader Pharmacology.
Her biological study spans a wide range of topics, including Pediatrics and Immunology.
She most often published in these fields:
- Internal medicine (55.79%)
- Adverse effect (26.58%)
- Tolerability (25.26%)
What were the highlights of her more recent work (between 2014-2018)?
- Internal medicine (55.79%)
- Tolerability (25.26%)
- Pharmacotherapy (21.32%)
In recent papers she was focusing on the following fields of study:
Gillian M. Keating mainly investigates Internal medicine, Tolerability, Pharmacotherapy, Adverse effect and Surgery.
Her Internal medicine research is multidisciplinary, relying on both Gastroenterology, Endocrinology, Oncology and Pharmacology.
Her Tolerability research includes themes of Anesthesia, Imatinib, Clinical endpoint and Adenocarcinoma.
Her Pharmacotherapy research is multidisciplinary, incorporating elements of Clinical trial, Dasatinib, Cardiology, Immunology and Pediatrics.
The study incorporates disciplines such as Diclofenac, Neuropathic pain, Kidney disease, Urology and Quality of life in addition to Adverse effect.
The various areas that Gillian M. Keating examines in her Surgery study include Bone mineral, Ibandronic acid, Risedronate Sodium and Cumulative incidence.
Between 2014 and 2018, her most popular works were:
- Sorafenib: A Review in Hepatocellular Carcinoma. (95 citations)
- Dexmedetomidine: A Review of Its Use for Sedation in the Intensive Care Setting. (92 citations)
- Apremilast: A Review in Psoriasis and Psoriatic Arthritis (68 citations)
In her most recent research, the most cited papers focused on:
- Internal medicine
- Cancer
- Disease
Gillian M. Keating mostly deals with Internal medicine, Adverse effect, Tolerability, Anesthesia and Surgery.
Her Internal medicine research incorporates themes from Gastroenterology, Endocrinology and Oncology.
She has included themes like Spasticity and Kidney disease in her Adverse effect study.
Gillian M. Keating interconnects Lightheadedness, Norepinephrine and Supine hypertension, Pure autonomic failure, Orthostatic vital signs in the investigation of issues within Tolerability.
Her research in the fields of Tizanidine overlaps with other disciplines such as Dronabinol, Delta-9-tetrahydrocannabinol and Cannabidiol.
The Surgery study combines topics in areas such as Safety profile, Hepatocellular carcinoma, Sorafenib and Inflammatory bowel disease.
This overview was generated by a machine learning system which analysed the scientist’s
body of work. If you have any feedback, you can
contact us
here.
